Evidence map›Paper›PMID 42220083›Full record

ArticleCancer reports (Hoboken, N.J.)2026

MITF Gain-of-Function Mutation in Metastatic Prostate Cancer: A Rare Finding With Potential Therapeutic Significance.

Paul J Pecorin, Nyembezi Dhliwayo, Matthew Demetrious, Ludimila Cavalcante, Veronica Rodriguez-Bravo, Josep Domingo-Domenech, Thomas Westbrook

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Paul J PecorinDivision of General Internal Medicine, Department of Medicine, Rush University Medical Center, Chicago, Illinois, USA.ORCID 0009-0002-3878-6240
Nyembezi DhliwayoDivision of Hematology, Medical Oncology and Cell Therapy, Department of Medicine, Rush University Medical Center, Chicago, Illinois, USA.ORCID 0009-0005-3428-2530
Matthew DemetriousDepartment of Pathology, Rush University Medical Center, Chicago, Illinois, USA.ORCID 0009-0004-7560-9598
Ludimila CavalcanteDivision of Hematology & Oncology, Department of Medicine, University of Virginia, Charlottesville, Virginia, USA.ORCID 0000-0002-9676-0789
Veronica Rodriguez-BravoDepartment of Urology, Mayo Comprehensive Cancer Center, Rochester, Minnesota, USA.
Josep Domingo-DomenechDepartment of Urology, Mayo Comprehensive Cancer Center, Rochester, Minnesota, USA.ORCID 0000-0002-7870-7511
Thomas WestbrookDivision of Hematology, Medical Oncology and Cell Therapy, Department of Medicine, Rush University Medical Center, Chicago, Illinois, USA.ORCID 0009-0009-8107-4055

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProstate cancer is the most common non-cutaneous malignancy in men and remains a leading cause of cancer-related mortality, particularly in aggressive variants. These tumors are usually associated with alterations in TP53, RB1, and PTEN. The microphthalmia-associated transcription factor (MITF) has been implicated in several malignancies, but its role in prostate cancer is less defined. CASE: We report the first case of metastatic prostate adenocarcinoma harboring a gain-of-function MITF E318K mutation. The patient presented with high tumor burden, rapid progression, and evidence of tumor heterogeneity. The E318K mutation, previously linked to melanoma and renal cell carcinoma, enhances MITF transcriptional activity and may contribute to aggressive disease behavior.

conclusionThis case expands current understanding of MITF in prostate cancer and raises important questions regarding its prognostic and therapeutic significance.

Indexed as

AdenocarcinomaGain of Function MutationMicrophthalmia-Associated Transcription FactorProstatic NeoplasmsHumansMaleMicrophthalmia-Associated Transcription FactorMITF protein, human

Identifiers

PMID42220083
PMCPMC13238700

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.